<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01593644</url>
  </required_header>
  <id_info>
    <org_study_id>ADEN-Ph2-2011-1</org_study_id>
    <nct_id>NCT01593644</nct_id>
  </id_info>
  <brief_title>Phase II Study for the Diagnosis and Functional Assessment of CAD Using Transthoracic-Echodoppler</brief_title>
  <official_title>Phase 2, Monocentric, Single Blind Study, Comparing the Efficacy and Tolerance of a Dipyridamole/Adenosine Combination Given Intravenously, as a Slow Bolus and at Low Doses to Adenosine Alone for Coronary Flow Reserve Assessment (in Patients With Stable Ischemic Heart Disease) Using Transthoracic Echodoppler</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Adenobio N.V</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Adenobio N.V</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and tolerance of a&#xD;
      dipyridamole/adenosine combination given intravenously, as a slow bolus and at low doses to&#xD;
      adenosine alone (given at its recommended dosage adjusted to patients' weight) for coronary&#xD;
      flow reserve assessment (in 60-75 patients with stable ischemic heart disease) using&#xD;
      transthoracic echodoppler&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase 2, monocentric, single blind study, comparing the efficacy (primary endpoint) and the&#xD;
      safety-tolerance profile (secondary endpoint) of a dipyridamole/adenosine combination given&#xD;
      intravenously as a slow bolus and at low doses to adenosine alone given by the same route at&#xD;
      its standard and recommended dose.&#xD;
&#xD;
      Expected results: Non inferiority of the combination compared to standard adenosine alone in&#xD;
      terms of hemodynamic efficacy, with maintenance of the optimal hyperemic coronary effect for&#xD;
      at least 45 to 60 seconds after the end of the injection -Significant reduction of the&#xD;
      incidence rate of A1 adverse events and of the severity of A2 and A1 clinical symptoms.&#xD;
&#xD;
      Primary endpoint : diastolic mean and peak coronary blood velocities Secondary endpoint :&#xD;
      incidence rate and severity of adverse events, in particular, chest pain, dyspnoea,&#xD;
      hypotension, bradycardia, AV blocks, arrhythmia&#xD;
&#xD;
      Number of patients: 60-75 pts with 42-50 pts acceptable for statistical analysis&#xD;
&#xD;
      Operating procedures:&#xD;
&#xD;
      Day 1 (visit): Informed consent signature, Review of inclusion and exclusion criteria,&#xD;
      Hemodynamic variables and EKG, Cardiac history, Significant other medical diseases, Risk&#xD;
      factors, Concomitant treatment and substances consumed within 48 hours, Transthoracic&#xD;
      ultrasonography, Adverse events report Day 2 (telephone contact): Adverse events report&#xD;
&#xD;
      Duration of the study: 15 months&#xD;
&#xD;
      Statistical Analysis: Statistical tests will include :a paired test analysis and comparison&#xD;
      of the means (quantitative variables) -Possibly the Mac-Nemar test for the assessment of&#xD;
      clinical adverse events during the study test with both products.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2011</start_date>
  <primary_completion_date type="Anticipated">March 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Diastolic mean and peak coronary blood velocities</measure>
    <time_frame>2 minutes</time_frame>
    <description>hemodynamic efficacy, with maintenance of the optimal hyperemic coronary effect for at least 45 to 60 seconds after the end of the injection</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence rate and severity of adverse events, in particular, chest pain, dyspnoea, hypotension, bradycardia, AV blocks, arrhythmia.</measure>
    <time_frame>24 hours</time_frame>
    <description>Incidence rate of A1 adverse events and of the severity of A2 and A1 clinical symptoms</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Ischemic Heart Disease</condition>
  <arm_group>
    <arm_group_label>adenosine + dypiridamole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>adenosine + dipyridamole</intervention_name>
    <description>adenosine / dipyridamole combination given intravenously as a slow bolus at low doses</description>
    <arm_group_label>adenosine + dypiridamole</arm_group_label>
    <other_name>Adenosine : Krenosin® vials with 6 mg of adenosine in 2 ml fluid</other_name>
    <other_name>concentration of 3 mg /ml)</other_name>
    <other_name>Dipyridamole : injectable Persantine® - vials of 10 mg/2 ml</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Man or post-menopausal woman or with an oral contraceptive treatment , &gt; 18 years&#xD;
&#xD;
          -  Provided written consent by patient with good understanding of the study objectives as&#xD;
             explained by the investigator during the initial visit&#xD;
&#xD;
          -  Patient with a potential or known Coronary Artery Disease&#xD;
&#xD;
          -  Patient for whom transthoracic ultrasonography for coronary reserve assessment is&#xD;
             deemed useful&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects under 18, pregnant or breast-feeding woman, psychotic patients or subjects&#xD;
             placed under administrative and legal authority&#xD;
&#xD;
          -  Patients judged by investigator as not able to understand the study objectives&#xD;
&#xD;
          -  Patients with a medical history, in particular a heart disease history (eg AV block)&#xD;
             judged as non eligible by investigator&#xD;
&#xD;
          -  Patients whose medical treatment contra- indicates their inclusion in the study (eg&#xD;
             chronic use of oral dipyridamole, pentoxifylline), if not stopped at least 72 hours&#xD;
             before the study test&#xD;
&#xD;
          -  Patients with symptomatic bradycardia (&lt;40 beat/min) or with systemic hypotension (SBP&#xD;
             &gt; 90 mmHg&#xD;
&#xD;
          -  Patients with a 2nd and 3rd degree AV block, a sick sinus syndrome, but not those with&#xD;
             artificial pacemaker&#xD;
&#xD;
          -  Patients with prolonged QT (QTc&gt;480 ms)&#xD;
&#xD;
          -  Patients with oral dipyridamole who did not stopped their medication 48hrs before the&#xD;
             study test&#xD;
&#xD;
          -  Patients who received theophylline within 5 days before study test&#xD;
&#xD;
          -  Consumption of coffee, cola, tea, chocolate within 12 hrs before study test&#xD;
&#xD;
          -  Patients with a history of unstable Asthma or Chronic Obstructive Pulmonary Disease&#xD;
             with bronchoconstriction&#xD;
&#xD;
          -  Patients with unstable angina pectoris or uncontrolled severe heart failure&#xD;
&#xD;
          -  Patients with a recent myocardial infarction history (&lt;7 days), or stroke episode (&lt; 1&#xD;
             month)&#xD;
&#xD;
          -  Patients with known TC stenosis and not yet revascularized, uncontrolled hypovolemia,&#xD;
             known and unfixed valvular stenosis, left-right shunt, pericarditis, sympathetic&#xD;
             nervous system dysfunction, carotid stenosis , any significant cerebrovascular&#xD;
             insufficiency&#xD;
&#xD;
          -  Patients with known allergy to adenosine or dipyridamole&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick Meimoun, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier de Compiègne</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Philippe GORNY, PhD,MD</last_name>
    <phone>+33 616 764 464</phone>
    <email>pg@adenobio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre Hospitalier de Compiègne</name>
      <address>
        <city>Compiègne</city>
        <zip>60321</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick MEIMOUN</last_name>
      <phone>+33 3 44 23 62 39</phone>
      <email>p.meimoun@ch-compiegne.fr</email>
    </contact>
    <investigator>
      <last_name>Patrick MEIMOUN, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <study_first_submitted>May 6, 2012</study_first_submitted>
  <study_first_submitted_qc>May 7, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 8, 2012</study_first_posted>
  <last_update_submitted>September 6, 2012</last_update_submitted>
  <last_update_submitted_qc>September 6, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 7, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dipyridamole/adenosine combination given intravenously</keyword>
  <keyword>slow bolus and low doses</keyword>
  <keyword>coronary flow reserve assessment</keyword>
  <keyword>transthoracic echodoppler</keyword>
  <keyword>Patients</keyword>
  <keyword>stable</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenosine</mesh_term>
    <mesh_term>Dipyridamole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

